GoodRx announced the availability of new affordability programs for menopause hormone therapies from Pfizer. These programs aim to broaden access and affordability for crucial medications for women.
Eligible patients with a valid prescription can now find low cash prices for brand-name menopause hormone therapies, ranging from $99 to $249, at over 70,000 pharmacies nationwide exclusively through GoodRx. This addresses a significant financial burden, as GoodRx research indicates menopause medication list prices have increased by 58% since 2014.
This initiative underscores GoodRx's commitment to addressing healthcare inequalities, particularly for women who often face higher healthcare costs. By integrating these manufacturer programs, GoodRx continues to connect high-intent audiences with cost-effective treatment options.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.